It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We deliver precise ADMET insights early in discovery to reduce risk and guide smarter design, helping you create safer, more effective molecules faster.
ADMET properties determine how a drug behaves in the body. Predicting these characteristics, especially during lead optimization helps design molecules with improved profiles, address persistent liabilities, reduce attrition, and accelerate development.
Early ADMET prediction allows teams to make informed decisions, minimizing risk and speeding the path from leads to viable candidates. At Sygnature Discovery, our approach in combining scientific expertise with advanced computational tools, which includes QSAR modeling, machine learning, and literature-based approaches delivers accurate, actionable ADMET predictions early in the discovery process.
By identifying metabolic hotspots and guiding multi-parameter optimization using both proprietary and open-source models, our integrated strategy provides medicinal chemistry teams with the insights needed to design safer, more effective molecules with confidence, reducing attrition and accelerating development.
Our ADMET Prediction Services
Sygnature Discovery’s ADMET predictions combine expert experience with advanced AI/ML tools to reduce attrition, guide confident decisions, and deliver tailored, project-specific insights.
QSAR and Free-Wilson Models
We build custom QSAR and Free-Wilson models using project-specific or published data to predict ADMET properties and support multi-parameter optimization during compound design.
Machine Learning and AI
Our teams leverage machine learning and AI tools to create predictive models tailored to your project. Where sufficient data exists, we develop local, project-specific models that adapt throughout the DMTA cycle to refine performance.
Central Nervous System Multiparameter Optimization Including BBB Score
To guide the design of brain-penetrant molecules, we have implemented and validated our own version of the Central Nervous System Multiparameter Optimization (CNS MPO) approach originally developed by Pfizer, as well as the BBB Score from Gupta et al. Additional literature models for drug-likeness and other properties are also available, including AbbVie MPS and KiDS MPO.
DMPK Modelling
We provide PK and PK/PD modeling, as well as physiologically based pharmacokinetic (PBPK) modeling in collaboration with our DMPK group.
Working with Sygnature on ADMET predictions combines decades of experience with advanced AI/ML tools to minimize attrition, provide clear and interpretable insights for confident decision making, and deliver customizable solutions tailored to your project’s data and needs.
Experienced ADMET property prediction
With decades of experience combined with advanced tools, we minimize attrition and accelerate compound progression.
Improved Decision Confidence
We provide clear, interpretable insights to help chemists and project teams make informed design choices, reducing uncertainty and accelerating progress.
Customized Solutions
With access to commercial and proprietary AI/ML Model development capabilities which can be tailored to your data and project needs, we ensure rational predictions and confident decision making.
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
Molecular glues are transforming targeted protein degradation but optimization remains complex and resource-intensive. This poster presents an integrated computational chemistry workflow combining generative AI and physics-based modelling to enable faster, more rational molecular glue design and prioritization.
Tatiana Rosado Rosenstock, Hiromitsu Ohzeki, Shohei Kumagai, Natsuno Suda, Colin Sambrook Smith Abstract Target identification (Target ID) is a foundational, multi-disciplinary…
Journal Papers
FAQs
We predict a wide range of properties, including solubility, permeability, metabolic stability, clearance, and CNS penetration.
Both. We develop custom models using project data and apply validated models from leading software vendors and open-source platforms.
Our models and predictions are discussed across integrated and collocated project teams via secure platforms, enabling collaborative discussions, real-time feedback and confident iterative design cycles.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Combining AI-driven design, bespoke ML models and LLM-powered bioinformatics with hands-on collaboration to help you discover Optimized drug candidates faster.
